📊 Backtest📒 JournalUpdated 06/07/2026
← 🔥 Turbo
📐 Simulate Position
FRESHReport written today · at $90.00

CELC

ค่าขนมMID CAP
Celcuity Inc. · NASDAQ · Healthcare / Biotechnology
$90.00
▲ 2.80%
MCap $4.3B
11 days to PDUFA (Jul 17) · up ~677% over 52 weeks — approval optimism largely priced in, but Jul 17 remains a true binary gap event · mutant-cohort data (Jun 2) adds label-expansion optionality not yet in the WT-only NDA
BusinessOncology biotech · Gedatolisib pan-PI3K/mTOR inhibitor · FDA Priority Review NDA · PDUFA Jul 17, 2026 for HR+/HER2-/PIK3CA wild-type advanced breast cancer · VIKTORIA-1 mutant cohort doubled PFS vs alpelisib (Jun 2026)
Thesis

Celcuity's gedatolisib faces an FDA PDUFA decision on July 17, 2026 — 11 days away — for HR+/HER2-/PIK3CA wild-type advanced breast cancer under Priority Review and Real-Time Oncology Review. Phase 3 VIKTORIA-1 WT data published in J Clin Oncol showed practice-changing PFS gains; the Jun 2, 2026 PIK3CA-mutant cohort readout doubled median PFS vs alpelisib (11.1 vs 5.6 months, HR 0.50), opening a second regulatory path via sNDA in 2027. The stock has already re-rated ~677% over 52 weeks, so a clean approval may see a muted day-1 gap but a path toward the ~$161 analyst consensus (+79%); a CRL would crash 50%+ overnight. This is a ค่าขนม binary — size 2–3% max, not a trend trade.

📝 Primary Verdict · Core Holding
SPECULATIVEค่าขนม

ค่าขนม SPECULATIVE — 2-3% max given true binary gap risk at Jul 17 PDUFA. Approval path → $135-161 (+50% to +79%), full re-rate Moon → $270 (+200% on launch + mutant label optionality). CRL crashes to ~$40 (-55%). Size for the loss, not the stop.

88
score / 100 ⓘ
⚡ Catalyst
💊 FDA PDUFA Decision — Gedatolisib (PIK3CA Wild-Type ABC)11 DAYS

FDA target action date for gedatolisib NDA in HR+/HER2-/PIK3CA wild-type advanced breast cancer after CDK4/6 inhibitor + aromatase inhibitor progression. Priority Review, Breakthrough Therapy, Fast Track, and RTOR submission based on Phase 3 VIKTORIA-1 WT cohort data.

Jul 17, 2026
🧬 VIKTORIA-1 PIK3CA-Mutant Cohort — sNDA FilingQ3 2026

Jun 2, 2026 detailed data: gedatolisib triplet median PFS 11.1 mo vs 5.6 mo for alpelisib + fulvestrant (HR 0.50, p<0.0001); ORR 48.9% vs 26.0%. Celcuity plans supplemental NDA filing Q3 2026 — regulatory decision expected ~2027, materially expanding addressable population beyond the Jul 17 WT label.

Q3 2026
🚀 Commercial Launch — WT IndicationH2 2026

Company preparing for potential U.S. commercial launch in Q3 2026 if Jul 17 PDUFA clears. First-in-class pan-PI3K/mTOR inhibitor vs single-target alpelisib (Piqray) — launch execution, payer access, and prescriber adoption become the next re-rate driver post-approval.

Q3 2026
📊 VIKTORIA-2 — First-Line Expansion TrialONGOING

Phase 3 trial (n~1,180) evaluating gedatolisib + CDK4/6 inhibitor + fulvestrant as first-line treatment for endocrine-resistant HR+/HER2- ABC. Long-dated pipeline optionality beyond the post-CDK4/6 setting targeted by the Jul 17 NDA.

2027+
🎯 Entry Point
Entry 1
$90.00
Current screen price — 11 days to PDUFA, limited time to wait for a deep dipNow (2-3% max, pre-binary)
Entry 2PREFERRED
$76–80
Pre-PDUFA de-risking dip — preferred zone if broader market wobbles into Jul 17If dips this week
Entry 3
$40.50
Post-CRL crash zone — only for high-conviction re-entry on a clear resubmission pathOnly after a CRL
✅ Take Profit
TP1
Base-minus — clean approval but sell-the-news fade given 677% 52-wk run
$135
+50%
TP2
Base — approval + drift toward ~$161 analyst consensus
$161
+78.9%
TP3 🌙
Moon — approval + Q3 launch execution + mutant-cohort sNDA re-rate toward peak-sales bull case
$270
+200%
🔴 Stop Loss
Tight Stop
Pre-PDUFA thesis breach — sentiment souring ahead of Jul 17, data unchanged
$73.8
-18%
Hard Stop
CRL / rejection scenario — this is a gap, not a level; tight stop will not fill on a CRL
$40.5
-55%
Risk / Reward
Preferred entry ($76) vs TP2 ($161), risk sized to tight stop ($62.32), not the CRL gap
6.2 : 1
⚠ Binary event — size for the hard-stop loss scenario, not the tight stop ✅
📅 Estimate Date
FDA PDUFA Decision — Gedatolisib WT
Priority Review NDA for HR+/HER2-/PIK3CA WT ABC post-CDK4/6 — RTOR submission
Jul 17, 2026
Approval favored, not guaranteed
Commercial Launch Planning
Company targeting U.S. launch readiness if Jul 17 clears
Q3 2026
Contingent on approval
PIK3CA-Mutant sNDA Submission
Based on VIKTORIA-1 MT cohort data (PFS HR 0.50 vs alpelisib)
Q3 2026
Regulatory decision ~2027
📈 Possible Up % — Scenario Spread
Bear
-55%
$40.5
Base
+79%
$161
Bull
+110%
$189
Moon
+200%
$270
← downsideupside →
🏛️ Fed / Macro Risk — LOW

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook
FDA PDUFA decisions are event-driven, not rate-sensitive — the Jul 17 outcome will move CELC independent of Fed policy.
Inflation
Oncology drug pricing is largely insulated from near-term CPI prints; payer/formulary negotiation and competitive positioning vs alpelisib/capivasertib matter more than macro inflation.
Sector Impact
LOW direct Fed impact on the PDUFA event itself. The broader hawkish-Fed backdrop compresses high-multiple biotech valuations, but a clean Jul 17 approval with a commercially useful label would likely override sector headwinds; a CRL would not get the benefit of the doubt.
Summary
Fed risk is LOW for the Jul 17 binary itself — this is a pure regulatory catalyst. Sector-wide biotech multiple compression is a secondary headwind, not the driver of the PDUFA gap.
🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (12 analysts)
Strong Buy$161+79%
Craig-Hallum
Buy$171+90%
H.C. Wainwright
Buy$185+106%
Wells Fargo
Overweight$183+103%
current price $90.00
🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

TVTX✅ GoodApr 2026
+34%
in 1 day
Filspari FDA Approval — Expanded FSGS Label
Day-1 +33.77% on a rare-disease/oncology-adjacent biologic approval with a broader-than-expected label — closest direct FDA approval comp for a single-asset biotech re-rate post-PDUFA.
TVTX✅ GoodApr-May 2026
+46%
in 30 days
Filspari 30-Day Post-Approval Momentum
Approval momentum kept building as commercial launch details emerged — CELC could see a similar extended drift toward $161+ if gedatolisib clears Jul 17 with a commercially useful WT label, even if day-1 is muted.
MRUS⚡ MixedDec 2024
+2%
in 1 day
Bizengri FDA Accelerated Approval — NRG1+ NSCLC/Pancreatic
Cautionary sell-the-news comp: MRUS rose only +1.8% on its first FDA approval because optimism was largely pre-priced. Relevant for CELC given the 677% 52-week run — approval alone may not be enough; label breadth and launch clarity matter.
IMGN✅ GoodMay 2023
+129%
in 1 day
MIRASOL Phase 3 Confirmatory Win — Elahere Ovarian Cancer
Oncology binary upside comp: IMGN more than doubled (+129%) on landmark Phase 3 survival data — shows how much oncology names can re-rate when clinical data rewrites the commercial thesis. CELC's mutant-cohort beat of alpelisib (Jun 2026) is the analogous data catalyst; Jul 17 PDUFA is the regulatory binary on top.
⚡ Optional Layer · Tactical Overlay
🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-18% / -55%) only when trading the earnings spot — not for the core holding (use the -18% / -55% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern
+677% (52-wk, largely done)Already largely priced — 11 days to PDUFA

CELC has already captured an extreme pre-PDUFA run-up (~677% over 52 weeks) — far beyond the typical +5-15% drift biotechs see in the final 2-4 weeks before a decision. Further upside into Jul 17 is limited; the binary is increasingly about the gap on the readout itself, not additional run-up.

🎲Historical Post-Catalyst Move
✅ Catalyst Winavg +25%
range: +15% to +46%· Apr 2026 (TVTX); Dec 2024 (MRUS sell-the-news)
Travere (TVTX) Filspari FSGS approval (Apr 2026): +33.77% day-1, extending to +46% over 30 days. CELC's massive pre-run makes a muted day-1 (+15-25%) more likely even on approval, with extended drift toward analyst targets ($161, +79%) if launch details impress. Merus (MRUS) Bizengri approval (Dec 2024) rose only +1.8% day-1 — cautionary sell-the-news comp when optimism is pre-priced.
❌ Catalyst Missavg -52%
range: -40% to -60%· Historical CRL pattern, single-asset oncology biotech
Single-asset biotechs with priced-in approval optimism typically crash 40-60% same day on a CRL, as the market re-rates the entire near-term pipeline toward a much lower approval probability.
💼Spot Position Sizing
How the recommended % is derived
3%
of portfolio

3% max — ค่าขนม play with genuine binary gap risk. Even Priority Review + clean Phase 3 data + Breakthrough Therapy designation does not rule out a CRL. Size for the -55% hard-stop scenario, not the pre-event tight stop.

🛑Stop Loss · Spot Trade
Spot cut-loss levels — separate from the core holding
Before Catalyst
-18%($73.8)
หลุด $73.80 ก่อน PDUFA = conviction เปลี่ยนแม้ event ยังไม่เกิด
After Catalyst (Bad Result)-55%
ถ้า CRL ออกมา = exit ทันที ไม่ต้องรอ resubmission — อาจใช้เวลาเป็นปี
📎 Sources

Generated 2026-07-06 · Not financial advice